Anton Syndrome

Anton Syndrome, also called Anton–Babinski syndrome or visual anosognosia, is a rare neurological condition in which a person with cortical blindness adamantly denies their vision loss and often fabricates descriptions of what they “see.” This denial occurs despite clear evidence of blindness, such as walking into obstacles, and arises from damage to the primary visual cortices in both occipital lobes, coupled with disruption of pathways that connect visual processing areas to those responsible for awareness and language NCBIRadiopaedia.

Anton syndrome, or Anton–Babinski syndrome, is a rare neurological condition in which individuals with cortical blindness adamantly deny their loss of vision and often confabulate visual experiences to fill the gap in perception. It arises from bilateral damage to the occipital lobes—the brain’s primary visual processing centers—most commonly due to ischemic stroke of the posterior cerebral arteries. Despite clear evidence of blindness (they may walk into objects, miss visual cues, or fail visual exams), patients sincerely believe they can see, creating elaborate but incorrect descriptions of their surroundings EyeWikiNCBI.

Types

Classical Anton Syndrome (Complete Cortical Blindness):
In this form, there is total loss of vision due to bilateral lesions of the primary visual cortex. Patients are entirely cortically blind but insist they can see, often confabulating scenarios to fill in missing visual information NCBI.

Partial Anton Syndrome (Incomplete Cortical Blindness):
Here, some islands of vision (often peripheral) remain intact. Vision may fluctuate, and patients still deny their impairment and confabulate, reporting normal vision even though detailed testing shows field defects or “tunnel vision” Radiopaedia.

Atypical or Variant Anton Syndrome:
Rarely, Anton Syndrome presents in contexts other than occipital infarction—such as post-radiation injury, neoplastic processes, or metabolic disorders—where cortical blindness develops alongside denial and confabulation, but with additional atypical features like transient onset or mixed sensory deficits FrontiersNCBI.

Causes

1. Ischemic Stroke of Bilateral Occipital Lobes:
   Infarction within both posterior cerebral artery territories is the most common cause, leading to sudden loss of cortical vision and ensuing denial NCBI.

2. Cardiac Surgery–Related Embolic Events:
   Microemboli during procedures such as valve replacement can lodge in occipital cortices, causing cortical blindness and anosognosia NCBI.

3. Cerebral Angiography–Induced Ischemia:
   Contrast or catheter-related complications may precipitate bilateral occipital ischemia, resulting in Anton Syndrome NCBI.

4. MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes):
   Stroke-like episodes in MELAS can acutely damage the visual cortex, leading to cortically blind presentations with denial of blindness NCBI.

5. Preeclampsia and Eclampsia:
   Severe hypertensive disorders of pregnancy, often with posterior reversible encephalopathy syndrome (PRES), can injure occipital lobes and trigger Anton Syndrome NCBI.

6. Obstetric Hemorrhage:
   Massive blood loss causing hypotension can lead to watershed infarcts in occipital regions, producing cortical blindness with visual anosognosia NCBI.

7. Adrenoleukodystrophy:
   Early-stage demyelination in X-linked adrenoleukodystrophy can extend into occipital areas, causing denial of visual loss NCBI.

8. Hypertensive Encephalopathy:
   Acute, severe hypertension may precipitate posterior reversible encephalopathy with cortical involvement and resultant Anton Syndrome NCBI.

9. Central Nervous System Angiitis (Autoimmune Vasculitis):
   Inflammatory vasculitis of cerebral vessels can lead to multifocal infarcts including occipital damage and associated anosognosia NCBI.

10. Multiple Sclerosis:
    Demyelinating plaques in optic radiations or occipital lobes can cause cortical blindness with preserved ocular reflexes and denial NCBI.

11. Posterior Reversible Encephalopathy Syndrome (PRES) from COVID-19 Pneumonia:
    COVID-related endothelial injury may precipitate PRES with occipital involvement, leading to reversible Anton Syndrome NCBI.

12. Fat Embolism Syndrome:
    Embolic showers from long-bone fractures can occlude occipital microvasculature, triggering transient cortical blindness and anosognosia NCBI.

13. Trousseau Syndrome (Cancer-Associated Thrombosis):
    Hypercoagulability in malignancy—such as gallbladder cancer—can produce bilateral optic radiation infarcts and Anton Syndrome PMC.

Symptoms

1. Complete Denial of Vision Loss (Anosognosia):
   Patients insist they can see normally despite evidence to the contrary, reflecting disconnection between vision centers and awareness systems NCBI.

2. Visual Confabulation:
   Individuals fabricate detailed descriptions of visual scenes—despite cortical blindness—due to intact language and memory networks creating false perceptions NCBI.

3. Apparent Normal Ocular Reflexes:
   Pupillary light and accommodation reflexes remain intact because anterior visual pathways are undamaged NCBI.

4. Preserved Eye Movements:
   Voluntary and involuntary ocular motions (saccades, pursuits) occur normally since motor pathways bypass the primary visual cortex NCBI.

5. Collision with Objects:
   Patients frequently bump into furniture or walls, alerting caregivers to profound visual loss they refuse to acknowledge NCBI.

6. Mental Confusion or Disorientation:
   Sudden loss of vision combined with false beliefs about seeing may lead to confusion, frustration, or agitation NCBI.

7. Lack of Menace Reflex:
   There is no blink response to threatening gestures, confirming absence of cortical visual processing NCBI.

8. Stable Fundoscopic Examination:
   Ophthalmologic exam shows normal retina and optic nerve appearance, distinguishing cortical from ocular blindness NCBI.

9. Gun-Barrel Vision or Flickering Islands:
   In partial cases, small vision “islands” may persist, causing patients to report fleeting glimpses or tunnel vision NCBI.

10. Risk-Taking Behavior:
    Because patients believe they can see, they may engage in dangerous activities—like walking outdoors alone—leading to injuries NCBI.

Diagnostic Tests

Physical Examination

1. Light-Dark Discrimination Test:
   Assessing ability to distinguish light from dark confirms cortical involvement when failed despite intact eyes NCBI.

2. Menace Reflex Assessment:
   Waving a hand toward the eyes without touching checks blink response; absence indicates cortical blindness NCBI.

3. Pupillary Light Reflex Test:
   Shining light into each pupil ensures anterior pathways are intact despite cortical lesions NCBI.

4. Fundoscopic Examination:
   Ophthalmoscopy reveals a healthy retina and optic disc, indicating blindness arises in the brain NCBI.

5. Ocular Motility Evaluation:
   Observing saccades and smooth pursuit eye movements confirms motor control is preserved NCBI.

Manual Tests

6. Confrontation Visual Field Testing:
   Examiner presents fingers in peripheral fields; failure to see confirms field loss despite patient’s denial Wikipedia.

7. Finger-Counting Test:
   Asking “How many fingers am I holding up?” evaluates basic detection; inability despite verbal insistence indicates cortical blindness Wikipedia.

8. Letter-Reading or Sign-Identification Test:
   Requesting identification of large letters or signs tests higher-order vision, which fails in Anton Syndrome Wikipedia.

9. Obstacle Navigation Task:
   Observing patient walking around objects checks functional vision; collisions confirm blindness Wikipedia.

Laboratory and Pathological Tests

10. Complete Blood Count (CBC):
    Screens for infection or hematologic disorders that could underlie encephalopathy NCBI.

11. Basic Metabolic Panel (Electrolytes, Glucose, Renal/Liver):
    Identifies metabolic derangements (e.g., hypoglycemia) that may precipitate cortical dysfunction NCBI.

12. Coagulation Profile (PT/INR, aPTT):
    Detects hypercoagulable states linked to bilateral occipital infarctions NCBI.

13. Serum Lactate Level:
    Elevated in mitochondrial disorders such as MELAS, which can present with Anton Syndrome NCBI.

14. Cerebrospinal Fluid (CSF) Analysis:
    Performed when infection or autoimmune vasculitis is suspected (e.g., TB meningitis cases) MedCrave Online.

Electrodiagnostic Tests

15. Visual Evoked Potentials (VEP):
    Measures cortical responses to visual stimuli; absent or severely attenuated waves indicate cortical blindness NCBI.

16. Electroencephalogram (EEG):
    May show loss of alpha rhythms over occipital regions and other nonspecific changes in cortical activity Deep Blue.

Imaging Tests

17. Non-Contrast Head CT:
    Rapid assessment to identify acute hemorrhage or large infarcts in occipital lobes Radiopaedia.

18. Brain MRI with Diffusion-Weighted Imaging:
    Sensitive detection of acute and chronic occipital infarcts and white matter changes Radiopaedia.

19. Magnetic Resonance Angiography (MRA):
    Evaluates posterior cerebral artery patency and other vascular anomalies contributing to cortical injury NCBI.

20. Echocardiogram:
    Rules out cardiac sources of emboli in patients with suspected stroke-induced Anton Syndrome NCBI.

Non-Pharmacological Treatments

Below are evidence-based therapies organized into Exercise Therapies, Mind-Body Approaches, and Educational Self-Management. For each, we describe the approach, its purpose, and underlying mechanism.

1. Visual Scanning Training
   Description: Guided practice in systematically moving eyes/head to scan the environment.
   Purpose: Enhance detection of objects and reduce collisions.
   Mechanism: Leverages neuroplasticity by repeatedly stimulating spared visual pathways and engaging attention networks PMC.

2. Saccadic Eye-Movement Exercises
   Description: Repetitive rapid eye movements between targets.
   Purpose: Improve voluntary control of gaze shifts.
   Mechanism: Strengthens residual ocular motor circuits to compensate for field deficits PMC.

3. Hand-Eye Coordination Drills
   Description: Tasks like catching a ball or reaching for objects.
   Purpose: Reinforce visuomotor integration despite impaired vision.
   Mechanism: Promotes multisensory relearning by coupling proprioceptive feedback with attempted visual input PMC.

4. Mobility and Orientation Training
   Description: Cane use and guided ambulation in varied environments.
   Purpose: Foster safe independent mobility.
   Mechanism: Teaches use of auditory and tactile cues to navigate when vision is lacking PMC.

5. Balance and Proprioceptive Exercises
   Description: Standing on foam pads, single-leg stance.
   Purpose: Reduce fall risk by enhancing stability.
   Mechanism: Compensates for visual loss via improved vestibular and somatosensory integration PMC.

6. Yoga
   Description: Gentle postures, breathing, and focus exercises.
   Purpose: Lower stress, improve attention and proprioception.
   Mechanism: Activates parasympathetic pathways and heightens body awareness SpringerOpen.

7. Tai Chi
   Description: Slow, flowing movements synchronized with breath.
   Purpose: Enhance balance and mindful movement.
   Mechanism: Stimulates neural circuits for postural control and attentional regulation SpringerOpen.

8. Guided Meditation
   Description: Focused attention on breath or sounds.
   Purpose: Reduce anxiety and improve cognitive clarity.
   Mechanism: Modulates default mode and salience networks, aiding acceptance of deficits SpringerOpen.

9. Mindfulness-Based Stress Reduction (MBSR)
   Description: Structured program of meditation and gentle yoga.
   Purpose: Cultivate nonjudgmental awareness of sensations.
   Mechanism: Boosts prefrontal regulation over limbic reactivity, supporting coping SpringerOpen.

10. Progressive Muscle Relaxation
    Description: Sequential tensing and releasing of muscle groups.
    Purpose: Alleviate muscle tension and related stress.
    Mechanism: Via biofeedback, reduces sympathetic overactivity SpringerOpen.

11. Patient Education Workshops
    Description: Group sessions explaining cortical blindness and coping strategies.
    Purpose: Increase insight and adherence to rehabilitation.
    Mechanism: Empowers patients through knowledge, enhancing self-efficacy.

12. Goal-Setting and Action Planning
    Description: Collaborative identification of functional goals.
    Purpose: Guide structured progression of therapy.
    Mechanism: Engages executive networks, reinforcing progress via measurable milestones.

13. Errorless Learning Techniques
    Description: Gradual task introduction with high initial support.
    Purpose: Build skills without discouragement from mistakes.
    Mechanism: Strengthens correct neural pathways through repeated success.

14. Environmental Modification
    Description: Adaptive lighting, high-contrast markings in the home.
    Purpose: Reduce hazards and improve usability.
    Mechanism: Leverages residual sensory input (contrast, light) to compensate for vision loss.

15. Assistive Technology Training
    Description: Use of screen readers, voice-activated devices.
    Purpose: Maintain communication and information access.
    Mechanism: Substitutes auditory for visual information, engaging language networks.

16. Support Group Participation
    Description: Peer meetings for shared experiences.
    Purpose: Reduce isolation and foster emotional support.
    Mechanism: Activates social cognition circuits and normalizes experiences.

17. Caregiver Education
    Description: Training family members in safe assistance.
    Purpose: Enhance home support and safety.
    Mechanism: Improves the rehabilitative environment via informed caregiving.

18. Structured Journaling
    Description: Daily logs of activities and challenges.
    Purpose: Track progress and identify triggers.
    Mechanism: Engages reflective capacity, aiding clinical adjustments.

19. Cognitive-Behavioral Techniques
    Description: Identifying and reframing negative thoughts about blindness.
    Purpose: Improve mood and motivate engagement.
    Mechanism: Adjusts dysfunctional beliefs via cognitive restructuring.

20. Music Therapy
    Description: Listening to or creating music with a therapist.
    Purpose: Enhance mood and attention.
    Mechanism: Stimulates reward and auditory networks, offsetting sensory loss.

---

Key Drugs

While no medication specifically targets Anton syndrome itself, treatment focuses on underlying causes (e.g., stroke prevention and neural protection). Below are ten evidence-based agents used in managing cortical blindness and its vascular origins:

1. Alteplase (tPA)

   • Class: Thrombolytic

   • Dosage: 0.9 mg/kg IV over 60 min (10% as bolus) within 4.5 h of stroke onset

   • Time Window: Acute phase of ischemic stroke

   • Side Effects: Intracranial hemorrhage, angioedema Medifind.

2. Aspirin

   • Class: Antiplatelet

   • Dosage: 81–325 mg orally once daily, starting 24–48 h post-stroke

   • Time: Chronic secondary prevention

   • Side Effects: Gastrointestinal bleed, dyspepsia Medifind.

3. Clopidogrel

   • Class: P2Y12 inhibitor

   • Dosage: 75 mg orally once daily

   • Time: Post-TIA or minor stroke for 21 days

   • Side Effects: Bleeding, rash Medifind.

4. Warfarin

   • Class: Vitamin K antagonist

   • Dosage: Adjusted to INR 2–3; typically 2–5 mg orally daily

   • Time: Atrial fibrillation-related stroke prevention

   • Side Effects: Bleeding, skin necrosis Medifind.

5. Atorvastatin

   • Class: HMG-CoA reductase inhibitor

   • Dosage: 40–80 mg orally once daily

   • Time: Secondary prevention post-stroke

   • Side Effects: Myopathy, elevated liver enzymes Medifind.

6. Edaravone

   • Class: Free radical scavenger

   • Dosage: 30 mg IV twice daily for 14 days (Japan)

   • Time: Acute ischemic stroke

   • Side Effects: Hepatic dysfunction, renal impairment Cureus.

7. Citicoline

   • Class: Neuroprotective agent

   • Dosage: 500 mg orally twice daily for 6–12 weeks

   • Time: Post-stroke recovery

   • Side Effects: Rare gastrointestinal discomfort Healthline.

8. Piracetam

   • Class: Nootropic

   • Dosage: 2.4–4.8 g orally divided TID

   • Time: Chronic cognitive support

   • Side Effects: Nervousness, weight gain Cureus.

9. Memantine

   • Class: NMDA receptor antagonist

   • Dosage: 5 mg orally once daily, titrate to 10 mg BID

   • Time: Cognitive symptoms post-stroke or in association with dementia

   • Side Effects: Dizziness, headache Cureus.

10. Selective Serotonin Reuptake Inhibitors (SSRIs)

    • Class: Antidepressant/neuroplasticity enhancer

    • Dosage: Fluoxetine 20 mg orally once daily

    • Time: Post-stroke depression and motor recovery

    • Side Effects: Nausea, sexual dysfunction SpringerOpen.

---

Dietary Molecular Supplements

These supplements support neural health, vascular integrity, and recovery mechanisms:

1. Omega-3 Fatty Acids (DHA/EPA)

   • Dosage: 1–2 g daily

   • Function: Anti-inflammatory, supports membrane fluidity

   • Mechanism: Modulates eicosanoid pathways, enhances neurovascular coupling MDPI.

2. Vitamin B₁₂ (Cobalamin)

   • Dosage: 1,000 µg IM weekly ×4 or 1 mg orally daily

   • Function: Myelin maintenance, DNA synthesis

   • Mechanism: Reduces homocysteine, supports oligodendrocyte function MDPI.

3. Folate (Vitamin B₉)

   • Dosage: 400–800 µg daily

   • Function: Reduces stroke risk, supports methylation

   • Mechanism: Lowers homocysteine, enhances endothelial health PMC.

4. Vitamin B₆ (Pyridoxine)

   • Dosage: 50 mg daily

   • Function: Neurotransmitter synthesis

   • Mechanism: Coenzyme in GABA and dopamine pathways PMC.

5. Vitamin D₃

   • Dosage: 1,000–2,000 IU daily

   • Function: Neuroprotective, immune modulation

   • Mechanism: Regulates neurotrophic factors and reduces inflammation PMC.

6. Coenzyme Q₁₀

   • Dosage: 100 mg twice daily

   • Function: Mitochondrial energy support

   • Mechanism: Antioxidant, stabilizes mitochondrial membranes PMC.

7. Curcumin

   • Dosage: 500 mg twice daily with piperine

   • Function: Anti-inflammatory, antioxidant

   • Mechanism: Inhibits NF-κB, reduces oxidative damage PMC.

8. Resveratrol

   • Dosage: 150–300 mg daily

   • Function: Vascular health support

   • Mechanism: Activates SIRT1, improves endothelial function PMC.

9. L-Carnitine

   • Dosage: 500 mg twice daily

   • Function: Mitochondrial fatty acid transport

   • Mechanism: Enhances ATP production, reduces lactic acidosis PMC.

10. Alpha-Lipoic Acid

• Dosage: 300–600 mg daily

• Function: Antioxidant recycling

• Mechanism: Regenerates glutathione and vitamins C/E PMC.

---

Advanced/Regenerative Therapies

1. Zoledronic Acid (Bisphosphonate)

• Dosage: 5 mg IV infusion over ≥15 min once yearly

• Function: Prevents bone loss in immobile patients

• Mechanism: Binds hydroxyapatite, inhibits osteoclast-mediated resorption MedscapeNCBI.

2. Teriparatide (Regenerative PTH Analog)

• Dosage: 20 µg SC once daily

• Function: Anabolic bone formation

• Mechanism: Intermittent PTH1 receptor activation stimulates osteoblasts to build new bone WikipediaNCBI.

3. Hyaluronic Acid (Viscosupplementation)

• Dosage: 16–30 mg intra-articular weekly ×3

• Function: Restores joint lubrication in osteoarthritic patients

• Mechanism: Replaces synovial HA, improves viscoelasticity and shock absorption MedscapeWikipedia.

4. Erythropoietin (Neuroregenerative Growth Factor)

• Dosage: 10,000 U SC thrice weekly

• Function: Neuroprotection and stem cell mobilization

• Mechanism: Anti-apoptotic effects, mobilizes endothelial progenitors ScienceDirect.

5. Umbilical Cord-Derived MSCs (Stem Cell Therapy)

• Dosage: 1×10⁶ cells/kg IV infusion in acute stroke trials

• Function: Promote functional recovery post-stroke

• Mechanism: Secrete trophic factors, modulate inflammation, support angiogenesis PMC.

6. Muse Cells (Multilineage-Differentiating Stress-Enduring Cells)

• Dosage: 1×10⁴ cells injected into infarct site (animal models)

• Function: Neuronal circuit reconstruction

• Mechanism: Integrate into host tissue, differentiate into neurons and glia Cell.

---

 Surgical Interventions

1. Craniotomy with Hematoma Evacuation

   • Procedure: Surgical opening of skull to remove occipital hemorrhage.

   • Benefits: Reduces intracranial pressure, preserves surrounding cortex.

2. Decompressive Craniectomy

   • Procedure: Removal of part of skull to allow brain swelling.

   • Benefits: Prevents herniation, minimizes secondary injury.

3. Posterior Cerebral Artery Bypass

   • Procedure: Microsurgical grafting to reroute blood flow around an occlusion.

   • Benefits: Restores perfusion to occipital lobes, may salvage vision.

4. Retinal Prosthesis Implantation

   • Procedure: Electronic device implanted on retina to transduce light.

   • Benefits: Partial restoration of visual perception in select patients.

5. Occipital Lobe Cortical Stimulation

   • Procedure: Implantation of electrodes to stimulate visual cortex.

   • Benefits: Experimental; may enhance visual network plasticity.

---

Prevention Strategies

1. Control Hypertension – Maintain BP <140/90 mmHg to reduce stroke risk.

2. Manage Diabetes – Keep HbA1c <7% to protect microvasculature.

3. Treat Dyslipidemia – Use statins for LDL <70 mg/dL in high-risk individuals.

4. Smoking Cessation – Eliminates an independent vascular risk factor.

5. Regular Exercise – At least 150 min/week moderate activity.

6. Healthy Diet – DASH or Mediterranean diet to lower vascular inflammation.

7. Weight Management – Aim for BMI 18.5–24.9 kg/m².

8. Anticoagulation for AF – Use DOACs or warfarin in atrial fibrillation.

9. Limit Alcohol – ≤1 drink/day women, ≤2 drinks/day men.

10. Head Injury Prevention – Use seat belts, helmets to avoid trauma.

---

When to See a Doctor

Seek immediate medical attention if sudden vision loss occurs, especially with confusion, headache, or neurological deficits. Early stroke care within the thrombolytic “golden hour” (first 4.5 hours) can be vision- and life-saving MedicineNet.

---

“Do’s” and “Don’ts”

1. Do maintain a safe home environment with clear pathways; Don’t argue about what the patient “should” see.

2. Do encourage rehabilitation exercises; Don’t force visual tasks beyond the patient’s capacity.

3. Do use high-contrast and tactile cues; Don’t leave sharp objects within reach.

4. Do foster social engagement; Don’t isolate the patient.

5. Do monitor mood changes; Don’t ignore signs of depression.

6. Do schedule regular follow-ups; Don’t skip vascular risk assessments.

7. Do support use of assistive technology; Don’t rely solely on verbal reassurance.

8. Do provide patient education; Don’t use technical jargon.

9. Do involve caregivers in therapy plans; Don’t overlook caregiver fatigue.

10. Do celebrate small gains; Don’t focus only on deficits.

---

Frequently Asked Questions

1. What triggers Anton syndrome?
   Primarily bilateral occipital lobe damage from stroke, but also trauma or encephalopathy.

2. Is recovery possible?
   Partial recovery may occur, especially in younger patients or non-vascular causes MedicineNet.

3. Can patients recognize their blindness?
   Insight often returns gradually as confabulations wane with neural recovery.

4. Why do they confabulate?
   The brain fabricates visual details to resolve sensory gaps due to cortical damage.

5. How is it diagnosed?
   MRI/CT confirming occipital injury plus neuro exam revealing denial of blindness.

6. Are there specific vision tests?
   Yes—Riddoch phenomenon testing and absence of pupillary reflex deficits.

7. Can medication reverse symptoms?
   No direct cure; treatment focuses on underlying cause and rehabilitation.

8. Is confabulation harmful?
   It impedes safety (e.g., falls), so therapeutic correction is crucial.

9. What specialists manage this?
   Neurologists, neuropsychologists, ophthalmologists, and rehabilitation therapists.

10. Does surgery help vision?
    Only if there’s treatable mass lesion (e.g., hematoma) compressing the occipital lobe.

11. How long is rehabilitation?
    Often months to years, tailored to individual progress.

12. Should family correct the patient?
    Gently, using education and supportive strategies rather than confrontation.

13. Can assistive devices help?
    Yes—talking devices, audio cues, and mobility aids improve safety.

14. What research is ongoing?
    Trials in stem cell therapy and cortical stimulation show promise.

15. Where can I find support?
    Stroke and low-vision support organizations offer resources for patients and caregivers.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: July 13, 2025.